STRATICELL SCREENING TECHNOLOGIES SA

Their core work

Straticell is a Belgian biotech SME specializing in advanced cell-based testing platforms — specifically human-derived iPSC cells and biocompatible 3D tissue scaffolds designed to replace or complement animal testing in cosmetic, dermatological, and pharmaceutical research. In the PLATFORMA project, they contributed expertise in peripheral nervous system tissue engineering, which also has applications in modeling neurological diseases such as ALS. Their involvement in InnCoCells as a third party indicates they also serve as a testing partner for cosmetic ingredient developers, bridging the gap between plant-based active ingredient production and validated safety or efficacy screening. In short, they are a niche testing specialist sitting at the intersection of tissue engineering, alternative methods toxicology, and the cosmetics industry.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (PLATFORMA, 2020), Straticell was firmly positioned in advanced human biology — iPSC cells, 3D scaffolds, nerve tissue models, and disease modeling for ALS. Their second involvement (InnCoCells, 2021 onward) shifts the context entirely to plant systems: cultivation, bioreactors, scale-up, and cascade bioprocessing of plant secondary metabolites. What stays constant across both is the cosmetics end-market — suggesting the core business is cosmetic testing services, and they are expanding their scope from human-tissue-based assays into evaluating plant-derived ingredients as well. The trajectory points toward becoming a full-service testing provider covering both the ingredient and the safety validation sides of cosmetic product development.

Straticell appears to be expanding from a tissue-model testing specialist into a broader cosmetic R&D service partner — combining human cell assays with plant-derived ingredient evaluation, which would make them relevant across the full cosmetic product pipeline.

How they like to work

Straticell has never coordinated an H2020 project — they join as a participant or third party, consistent with a specialist service provider that contributes specific testing or screening capabilities to consortia built around broader scientific goals. Their 24 unique partners across just 2 projects suggests they operate within large, multi-institutional consortia rather than tight bilateral arrangements. This profile fits a company that plugs testing expertise into research programs led by universities or larger industrial partners.

Straticell has connected with 24 distinct consortium partners across 11 countries through just two projects, reflecting participation in large, internationally distributed research consortia. No repeated partner patterns are visible at this data scale, suggesting their network is broad but not yet deep with recurring collaborators.

What sets them apart

Straticell occupies a rare niche: a private SME that combines human iPSC-based tissue engineering with cosmetic testing services — a combination far more typically found in academic labs than in commercial companies. Their dual footprint in both human-model-based safety testing and plant-derived ingredient development means they can serve cosmetic companies at two separate stages of R&D without switching partners. For consortia requiring an alternative-methods testing partner with credibility in both the pharma and cosmetics spaces, they are an unusual and potentially high-value node.

Highlights from their portfolio

• PLATFORMA
  Their only directly funded H2020 project (EUR 375,000), addressing peripheral nervous system tissue engineering with iPSC cells and 3D scaffolds — notable for combining cosmetic testing applications with ALS disease modeling in a single tissue platform.
• InnCoCells
  A longer-running project (2021-2025) in plant cell bioprocessing for cosmetics, where Straticell participates as a third party — signaling a strategic expansion into ingredient-side cosmetic R&D beyond their core testing expertise.